Anticancer metal drugs and immunogenic cell death

The clinically used anticancer metal drug oxaliplatin, in contrast with cisplatin, triggers the release of “find me” and “eat me” signals from dying cancer cells hence inducing immunogenic cell death and an anticancer vaccination effect. The activation of such immunomodulatory effects urgently needs to be established for experimental metal complexes.